“Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors”, J of Skin, vol. 7, no. 2, p. s177, Mar. 2023, doi: 10.25251/skin.7.supp.177.